Conversely, Aide et al., studying 32 patients affected by serous ovarian cancers, reported very weak PSMA expression levels in the entire dataset, concluding that PSMA cannot be used as a prognostic marker or a target for a theranostic strategy in this setting [103]. Here, FOLH1 is linked to ovarian serous adenocarcinoma.